FDA Accepts Neurocrine’s NDA for Parkinson’s Disease Drug

FDA Accepts Neurocrine’s NDA for Parkinson’s Disease Drug
Neurocrine Biosciences, Inc. NBIX announced that the FDA has accepted its new drug application (NDA) for opicapone as an adjunct therapy to levodopa/carbidopa to treat patients with Parkinson's ... read more
Source: Bing NewsPublished on 2019-07-11